1374994-81-6
Chemical Structure
NCS-MP-NODA
Synonym(s): NODA-Bz-SCN
- CAS No.: 1374994-81-6
- Formula:C18H24N4O4S
- Molecular Weight:392.47
InChIKey: CUZWESFCFFQUME-UHFFFAOYSA-N
SMILES: O=C(CN1CCN(CCN(CC1)CC2=CC=C(C=C2)N=C=S)CC(O)=O)O
Biological Activity: NCS-MP-NODA (NODA-Bz-SCN) is a NODA-derived bifunctional chelator. NCS-MP-NODA can conjugate with biomolecules including the RGD tripeptide, and is used for aluminum-[18F] fluoride-based positron emission tomography (PET) radiolabeling. NCS-MP-NODA can conjugate with the free lysine amino group of the PD-L1-specific peptide DK221 to generate DK222, which can be radiolabeled with 18F to form [18F]DK222. NCS-MP-NODA can be used in studies related to triple-negative breast cancer, melanoma and colon cancer[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NCS-MP-NODA | NCS-MP-NODA (NODA-Bz-SCN) is a NODA-derived bifunctional chelator. NCS-MP-NODA can conjugate with biomolecules including the RGD tripeptide, and is used for aluminum-[18F] fluoride-based positron emission tomography (PET) radiolabeling. NCS-MP-NODA can conjugate with the free lysine amino group of the PD-L1-specific peptide DK221 to generate DK222, which can be radiolabeled with 18F to form [18F]DK222. NCS-MP-NODA can be used in studies related to triple-negative breast cancer, melanoma and colon cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. San C, et al. Optimization study of a NODA derivative radiofluorination by Al18F complexation using a design of experiments approach[J]. Chemistry-A European Journal, 2023.
- [2]. San C, et al. Optimization of a 1,4,7-Triazacyclononane-1,4-diacetic acid (NODA) Derivative Radiofluorination by Al F Complexation Using a Design of Experiments Approach. Chemistry (Weinheim an der Bergstrasse, Germany). 2023 Dec 19;29(71):e202302745. [Content Brief]
- [3]. Kumar D, et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2107982118. [Content Brief]
Keywords
